CD274 and neoplasm: Between Feb 2018 and June 2019, 26 patients among PD-L1 positive patients (≥ 1%) were treated with pembrolizumab as a second-line therapy and they were evaluated the tumor response by computed tomography (CT) or magnetic resonance imaging (MRI).